In-line Nasal Delivery Device

ABSTRACT

A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.17/866,222, filed Jul. 15, 2022, which is a continuation of U.S. patentapplication Ser. No. 17/585,099, filed Jan. 26, 2022, which is acontinuation of U.S. patent application Ser. No. 15/759,447 (now U.S.Pat. No. 11,266,799) which is a National Stage Entry ofPCT/US2016/051169 filed Sep. 9, 2016, which claims priority to U.S.Provisional Patent Application No. 62/216,789 filed Sep. 10, 2015, thecontents of all of which are hereby incorporated by reference herein intheir entirety.

BACKGROUND

Depositing drug on the olfactory region of the nasal cavity is difficultto accomplish due to the complex architecture of the nasal cavity andthe turbinate guided air path for inhaled breath through the nose. Thesenatural structures act to prevent materials from depositing on theolfactory region as a way to protect this entry way into the centralnervous system (CNS). Nasal drop or spray devices, such as the Pfieffernasal spray devices (Radolfzell, Germany), are designed to saturate thelower nasal cavity. Drug deposited on the lower nasal cavity is absorbedinto the blood stream instead of the CNS, eliminating an advantage ofusing the nasal route for CNS delivery.

A more elegant approach to the intranasal delivery of compounds ormixtures is needed.

SUMMARY

Shown and described is one implementation of a device for the intranasaldelivery of a compound including a y-junction having a base, a firstbranch of the y-junction radiating from the base, a second branch of they-junction radiating from the base, a third branch of the y-junctionradiating from the base, and an internal dose loading channel of they-junction, a metered dose pump in fluid communication with the firstbranch of the y-junction, a conical spring associated with the secondbranch of the y-junction, a dose chamber in fluid communication with thethird branch of the y-junction, a nozzle associated with the dosechamber, a diffuser compression fit between the internal dose loadingchannel and the dose chamber, an actuator grip surrounding they-junction, and a housing, the y-junction residing within the housing.

In one aspect, the in-line nasal delivery device further includes apropellant canister in fluid communication with the second branch of they-junction and held by the actuator grip, the conical spring between thepropellant canister and the second branch of the y-junction.

In another aspect, the in-line nasal delivery device further includes avial in fluid communication with the metered dose pump.

In yet another aspect, the in-line nasal delivery device furtherincludes a pump fitment securing the metered dose pump to the vial.

In another implementation, shown and described is an in-line nasaldelivery device for the intranasal delivery of a compound including ahousing, the housing including a tip, an actuator, and a dose chamber,the tip and the dose chamber in fluid communication within the housing,a nozzle at a distal portion of the tip, the nozzle providing an outletfor the compound, and a pump in fluid communication with the dosechamber, the pump to move the compound into the dose chamber.

In one aspect, the in-line nasal delivery device further includes apropellant canister in communication with the housing, the propellantcanister having a propellant valve and in fluid communication with thedose chamber.

In another aspect, the in-line nasal delivery device further includes avial of compound cooperative with the pump to move the compound into thedose chamber.

In another aspect, the in-line nasal delivery device when actuatedcompresses the pump moving the compound into the dose chamber andactuation of the propellant valve disperses the propellant pushing thecompound providing for the compound to exit the device through thenozzle openings.

The invention will best be understood by reference to the followingdetailed description of various implementations, taken in conjunctionwith any accompanying drawings. The discussion below is descriptive,illustrative and exemplary and is not to be taken as limiting the scopedefined by any appended claims.

DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the advantages will be more readilyappreciated as the same become better understood by reference to thefollowing detailed description, when taken in conjunction with theaccompanying drawings, wherein:

FIG. 1 shows a cross section of the in-line nasal delivery device.

FIG. 2 shows a cross section of the in-line nasal delivery device in thestages of rest and actuation. FIG. 2A shows the in-line nasal deliverydevice at rest with FIG. 2B showing the actuation of the pump and FIG.2C showing actuation of the propellant valve.

FIG. 3 shows a cross section of another implementation of the in-linenasal delivery device.

FIG. 4 shows a cross section of the diffuser as seated within thedevice.

FIG. 5A shows an exploded view of the dose chamber and the y-junctionunassembled.

FIG. 5B shows an exploded view of the dose chamber and y-junction incooperation.

FIG. 6 shows arrows representing both dose and propellant flow.

FIG. 7 shows the actuator grip and conical spring arrangement.

FIG. 8 shows a cross section of the optional nose cone and a sideelevation of the optional nose cone.

DETAILED DESCRIPTION

When trade names are used herein, applicants intend to independentlyinclude the trade name product and formulation, the generic compound,and the active pharmaceutical ingredient(s) of the trade name product.

For clarity of disclosure, and not by way of limitation, the detaileddescription is divided into the subsections which follow.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art pertinent to the methods, apparatus and compositions described.As used herein, the following terms and phrases have the meaningsascribed to them unless specified otherwise:

“A” or “an” may mean one or more.

In one implementation, the in-line nasal delivery device 1 deliverscompound into the nasal cavity and deposits compound in the nasal cavitybeyond the nasal valve. The deposition includes the turbinates and/orthe olfactory region. The compound delivered is a liquid. The compoundmay be a drug, active pharmaceutical ingredient, or a pharmaceuticalformulation. The compound delivered may be a dose.

As shown in FIG. 1 , the in-line nasal delivery device 1 includes ahousing 10, diffuser 20, tip 35, nozzle 40, dose chamber 45, an actuator50, and a pump 25 to move the compound into the dose chamber 45. In oneaspect, the in-line nasal device 1 is associated and cooperative with apropellant canister 5, a propellant valve 15, and a vial 30 of compoundcooperative with the pump 25 to move the compound into the dose chamber45.

In one aspect, the diffuser 20 is a frit 21. The diffuser provides forthe conversion of the liquefied propellant in the propellant canister 5to gas and/or an increase in temperature of the propellant.

In one aspect, the propellant valve 15 is a metered dose propellantvalve 16.

In one aspect, the compound is supplied in the form of a sealed vial 30,e.g., of glass, that contains a quantity of liquid. In one aspect, thevial 30 has a neck 31 that is sealed by a removable closure 32 (notshown), for example but not limited to sealed with a plastic cover,crimped metal seal, and rubber stopper (for stability and sterilitypurposes). In one aspect, the vial 30 may contain the activepharmaceutical ingredient. When the closure 32 is removed, the device 1is engaged with the vial 30, in one aspect, by cooperation with the neck31 of the vial 30. A pump 25 moves the compound into the dose chamber45.

The propellant canister 5 is a canister of a compressed gas or aliquefied propellant. Compressed gases include but are not limited tocompressed air and compressed hydrocarbons. In one aspect, nitrogen orcarbon dioxide. Liquefied propellants include but are not limited tochlorofluorocarbons and hydrofluoroalkanes. The canister 5 willgenerally be provided with a propellant valve 15 by which the gas flowcan be controlled.

The tip 35 includes a nozzle 40. In one aspect, the nozzle 40 has aplurality of nozzle openings 41 (not shown). Thru the plurality ofnozzle openings 41, the compound and propellant is delivered to thenasal cavity.

Actuation of the propellant canister 5 is effectively coordinated withactuation of the pump 25 for the vial 30 for the compound. Thearrangement may be such that actuation of the vial 30 for the compoundcauses actuation of the propellant canister 5. FIG. 2 shows the device 1at rest (FIG. 2A) and in actuation (FIGS. 2B and 2C).

As an example, the staging of the device 1 actuation is as follows. Thehousing 10 is compressed to prime the propellant canister 5. When thehousing 10 is compressed, an actuator 50 remains stationary in thehousing 10 while the propellant canister 5 and the vial 30 move towardsthe actuator 50. At this time, the propellant valve 15 associated withthe propellant canister 5 is not actuated by compression. The actuator50 acts upon the pump 25 compressing the pump 25 and the compound fromthe vial 30 is moved into the dose chamber 45. After a majority of thecompound has moved into the dose chamber 45, the actuator 50 acts uponthe propellant valve 15 and the propellant valve 15 begins to compress.The continued depression of the actuator 50 releases the propellant fromthe propellant canister 5. The propellant pushes the compound as itexits the device 1 through the nozzle openings 41 of the nozzle 40located in the tip 35. The actuator 50 provides for first actuation ofthe pump 25, then once the pump 25 bottoms out, the continued depressionof the actuator 50 provides for release of the propellant from thecanister 5.

In an alternative implementation of the device 1 (not shown), the device1 does not include a diffuser 20.

FIG. 3 shows yet another implementation of the device 100. The device100 can deliver a single or multiple dose from a vial 30 or othercontainer. The device 100 allows for multiple doses to be delivered fromthe vial 30, or a single dose. For example, the vial 30 may contain avolume of compound for multiple doses, while the user may decide to onlydeliver a single dose from the vial 30. The compound may be a drug,active pharmaceutical ingredient, or a pharmaceutical formulation.

Initially, the vial 30 may be separate from the rest of the assembleddevice 100. At the time of use, the device 100 and vial 30 are taken outof their respective packaging. Prior to use, the vial 30 will generallybe sealed. In the aspect where the vial 30 is covered by a plasticcover, metal seal and stopper, the plastic cover and metal seal arepulled away from the top of the vial 30, and the rubber stopper isremoved from the vial 30. The vial 30 may be screwed into a pump fitment180 located at the base of the device 100. For example, but notlimitation, the vial 30 may have female threads which can be screwedinto male threads on a pump fitment 180, or vice versa. The vial 30 maycontain, for example but not limited to, inclusive of end points, 2-3ml, in another aspect 2-2.5 ml of compound.

As shown in FIG. 3 , the device 100 includes a housing 110. The housing110 contains components of the device 100 including the y-junction 120.The y-junction 120 has three branches radiating from a common base. They-junction and its three branches may be a molded component. They-junction 120 establishes both fluid and gas paths within the device100, and connects the metered dose pump 130, the dose chamber 150, andthe propellant canister 140 when the propellant canister 140 isassembled with the device.

As shown in FIG. 3 , for use of the device 100, the user will generallyorient the device 100 with the propellant canister 140 assembled andlocated at the top and the vial 30 assembled and located at the bottom.Housed within the device's 100 housing 110, the optional check-valve 160(attached to the metered dose pump 130 stem) press fits into a receivinghub of a first branch of the y-junction 120. An internal bore providesfluid communication from the metered dose pump 130, through the optionalcheck-valve 160 and y-junction 120, to the dose chamber 150. In oneaspect, the check valve 160 is an elastomeric component that installswithin a plastic housing between the metered dose pump 130 and they-junction 120. The optional check valve 160: (a) reduces or eliminatesdose leakage which could occur through the metered dose pump 130 if thepump stem was depressed and the propellant canister 140 was actuated;(b) allows for improved consistency in dose delivery by the device 100;and/or provides that compound is not pushed back down the internal doseloading channel 230 of the y-junction 120 and into the metered dose pump130.

When oriented as to be used in operation, housed within the device's 100housing 110, towards the top of the device 100, the propellant canister140 press fits into a second branch of the y-junction 120, establishingthe gas path through internal bores, through the diffuser 170 and to thedose chamber 150.

In this implementation of the device 100, the diffuser 170 is annular.As shown in FIG. 4 , the annular diffuser 170 sits inside a bore on theback end of the dose chamber 150. The external diameter of the annualdiffuser 170 is in a compression fit with the dose chamber 150. Aninternal dose loading channel 230 which is molded as a portion of they-junction 120 fits into the inner bore of the annual diffuser 170 whenthe dose chamber 150 is installed onto the y-junction 120. The innerdiameter of the annular diffuser 170 is in compression with the internaldose loading channel 230 portion of the y-junction 120. The annulardiffuser 170 is seated between the outer wall of the internal doseloading channel 230 and the inner wall of the dose chamber 150, sealingagainst both of those surfaces to form the bottom of the dose chamber150.

In one aspect, the diffuser 170 is a frit 171. The diffuser 170: (a)provides for the conversion of the liquefied propellant in thepropellant canister 140 to gas; (b) provides an increase in temperatureof the propellant; (c) acts to prevent the propellant from flowing backinto the device 100; (d) acts to prevent the compound from flowing backinto the device 100; and/or (e) acts to allows gas flow into the dosechamber 150 while preventing the compound from leaking out. The diffusermay be made of a porous polymer material.

The relationship in operation of the device 100 between the compound,the annular diffuser 170, the inner dose loading tube 230, the dosechamber 150 and the y-junction 120 are shown at least in FIG. 6 . Inoperation, the compound being loaded into the dose chamber 150 takes theless restrictive route, flowing out of the vial 30 and filling the dosechamber 150 rather than loading backwards through the annular diffuser170 and into the delivery path of the propellant of the y-junction 120.In operation of the device 100, the staging of operation and the amountof time required for operation of the device allows the annular diffuser170 to restrict compound from flowing back into the y-junction 120 forthe period of time needed, as the propellant canister 140 is activatedafter compound loading. During proper device 100 use, the entireactuation of the device 100, including metered dose pump 130 andpropellant canister 140, is approximately a second or less than asecond. The loaded dose in the dose chamber 150 does not have enoughtime to flow backwards into the y-junction 120. Immediately after thedose chamber 150 is full, the propellant expels the compound from thedevice 100.

On the third leg of the y-junction 120 at a 45-degree angle, the dosechamber 150 press fits into the y-junction 120, completing the flowpaths for both gas and fluid through the device. In one aspect, theangle is 30 degrees, 35 degrees, 40 degrees, 45 degrees, 50 degrees, 55degrees, 60 degrees, inclusive of endpoints and intervening degrees.

The y-junction 120 may contain engagement ribs (not shown) to helpsecure and position the assembly within the housing 110 of the device100.

The device 100 includes a pump fitment 180. The pump fitment 180 securesthe metered dose pump 130 to the vial 30 and holds both components inplace during device 100 use. One aspect of the pump fitment 180 is thatit consists of engagement ribs that retain it within the housing 110,provide vertical displacement, and prevent rotation during installationof the vial 30.

The device 100 includes a dose chamber 150. The dose chamber 150receives and stores the compound that has been pushed out of the innertube of the y-junction 120. When the propellant canister 140 isactuated, the y-junction 120 and dose chamber 150 are pressurized andthe propellant gas expels the compound out of the dose chamber 150. Asshown in FIGS. 5A and 5B, the dose chamber 150 is press fit into they-junction 120. The nozzle 190 is installed into the end of the dosechamber 150 opposite where it is press fit into the y-junction 120.

The nozzle 190 is installed into the distal end (end opposite where thedose chamber 150 is press fit into the y-junction 120) of the dosechamber 150, forming a liquid and gas-tight seal around the outerdiameter. During actuation of the device 100, propellant evacuatesliquid compound from the dose chamber 150, pushing it out the nozzle190.

The nozzle 190 forms the narrow plume angle (for example, an angle of 1to 40 degrees, including endpoints and angles intermittent therebetween; in one aspect the angle is 5 degrees, 10 degrees, 15 degrees,20 degrees, 25 degrees, 30 degrees, 35 degrees) multi-stream deposition.The nozzle 190 and resultant angle of the plume produced promotesdelivery of the compound to the olfactory region of the user's nasalcavity.

In this implementation, as shown in FIG. 8 , the device 100 may includean optional nose cone 200. The external geometries of the nose cone 200assist in providing proper alignment of the device 100 during insertioninto the nose. The diametrically opposed flat sides aid with placementagainst the septum of either naris, with the depth stop providingcorrect depth of insertion. The nose cone 200 adds redundancy to nozzle190 retention through mechanical interference incorporated into thedesign. As shown in FIG. 3 and FIG. 8 , there is an opening in the nosecone 200 which aligns with the nozzle 190. The nose cone 200 is not partof the pressurized flow path.

The housing 110 represents the body of the device 100. The housing 110includes two different “clamshells” concealing the components of thedevice 100 and retaining all components to ensure functionality. Thehousing 110 houses the metered dose pump 130 and pump fitment 180, theactuator grip 210, the y-junction 120, the propellant canister 140, andthe dose chamber 150. The nose cone 200 engages onto the outer geometryof the housing 110. The housing 110 is designed to assemble easilythrough the use of, for example but not limited to, mattel pins, snaps,post or screws, or a combination thereof, molded into the geometry.

The actuator grip 210 provides for actuation displacement by the user.The actuator grip 210 is composed of two parts, actuator grip A andactuator grip B and surround the y-junction 120 and reside within thehousing 110. FIG. 7 shows two finger grip notches 215 are designed intothe actuator grip 210 to allow the user to engage the device 100 withthe fingers, for example but not limited to, the index and middlefinger. These finger grip notches 215 allow the user to apply downwardmovement leading to device 100 actuation.

The metered dose pump 130 draws compound up from the vial 30 to they-junction 120. The metered dose pump 130 may utilize a custom pumpfitment 180 to promote functionality within the device 100, and allowattachment of the vial 30 via threads. The metered dose pump 130 maydeliver, for example but not limited to, volumes, 180 μl, 200 μl, or 230μl during actuation. Commercially available metered dose pumps 130 canbe used.

For the device 100 to consistently deliver compound, the metered dosepump 130 must first deliver compound, followed by propellant canister140 actuation to expel the compound. As shown in FIG. 7 , one manner inwhich to accomplish this is via a conical spring 220 between thepropellant canister 140 and y-junction 120 to create the necessarypropellant canister 140 actuation force resulting in the correct orderof actuation between the metered dose pump 130 and propellant canister140. In one implementation, a conical spring 220 is used, although thisforce is not limited to being produced by a conical spring 220 as othermechanisms can be used. In one aspect, the conical spring 220 has a nearzero preload, with a k value of about 25.5 lbf\in and a maximum load of3.21 bf. Selection of the spring or mechanism will include theconsiderations of: (a) providing for proper device 100 staging; (b)physical space in the device 100; and/or (c) and user feedback regardinghow stiff of a conical spring 220 still allows a variety of users toactivate the device 100.

The conical spring 220 is installed inline between the propellantcanister 140 and y-junction 120. The actuator grip 210 physically holdsthe propellant canister 140. The user activates the device 100 by, forexample, applying an in-line force acting down from the actuator grips210, and up from the vial 30. This force simultaneously acts to activateboth the metered dose pump 130 and the propellant canister 140. Theconical spring 220 acts in parallel to the internal propellant canisterspring, increasing the necessary force required to activate thepropellant canister 140. By choosing the conical spring 220 such thatthe necessary force required to actuate the propellant canister 140 isin excess of the maximum necessary force required to completely actuatethe metered dose pump 130, the device 100 provides that dose is loadedinto the dose chamber 150 before propellant gas begins to expel compoundfrom the device 100.

During device 100 actuation, the metered dose pump 130 draws liquidcompound up from the vial 30 at the bottom of the device 100 via they-junction 120, through the internal dose loading channel 230 and intothe dose chamber 150. The internal dose loading channel 230 provides aclear route for the compound to be loaded ahead of the annular diffuser170, without needed to physically pass through the porous material ofthe annular diffuser 170. As shown in FIG. 6 , small arrow headsrepresent the flow of the propellant while large arrow heads representthe flow of the compound. Priming shots may be required to completelyfill the metered dose pump 130 and internal dose loading channel 230 ofthe y-junction 120 prior to user dosing. A dose cap (not shown) maycover the nose cone 200 of the device 100 and captures the priming shotswhile also providing a means of visual indication to the user that thedevice is primed.

In the second stage of device 100 actuation, once the dose chamber 150has been filled, the propellant canister 140 releases propellant whichenters through the top of the y-junction 120, following the path shownby open arrow heads in FIG. 6 . The propellant flows physically throughthe porous material of the annular diffuser 170, which promotions in thevaporization of the propellant. The propellant first contacts thecompound at the distal (distal being closer to the nozzle 190, proximalbeing farther away from the nozzle 190) face of the annular diffuser 150as seated in the device 100. As the propellant continues to expand, itpushes the compound forward (toward the nozzle 190) in the dose chamber150, exiting though the nozzle 190 at the end of the dose chamber 150.

The propellant canister 140 provides the propulsive energy for thedevice 100. The stem of the propellant valve seats into the top receiverof the y-junction 120. During use, the user presses down on the actuatorgrips 210 which pulls the propellant canister 140 body down, actuatingthe propellant valve. This releases a metered volume of liquidpropellant. As the propellant vaporizes and expands, the compound isforced out of the dose chamber 150 and out through the nozzle 190.

As an example of propellant, but not limited to, the propellant canister140 uses HFA 134A as the propellant for the system. Other propellantsare envisioned. There are commercially available propellant canisters140.

The device 100, the propellant canister 140, and the vial 30 may all beincluded or provided together in a kit.

EXAMPLES AND EMBODIMENTS Example 1

The following table provides data on one implementation of the devicedescribed herein.

Dose Volume [μL] Shot # Device 1 Device 2 Device 3 Device 4 Device 5Device 6 1 190.6 193.7 185.3 199.2 199.2 145.1 185 uL + 10% 203.5 2181.4 205.5 178.9 167.7 167.7 141.7 185 uL − 10% 166.5 3 183.1 188.5173.3 165.6 165.6 138.5 185 uL + 15% 212.8 4 183.2 193.3 145.8 164.6164.6 136.6 185 uL − 15% 157.3 5 183.3 201.5 200.7 162.0 162.0 142.1 6185.8 207.7 166.3 179.4 179.4 138.9 7 184.3 195.1 180.3 164.8 164.8140.9 8 183.3 205.4 175.3 164.9 164.9 142.0 9 180.5 178.1 172.0 164.1164.1 141.8 10 179.7 204.0 178.0 170.6 170.6 143.9 Mean 183.5 197.3175.6 170.3 170.3 141.2 StDev 3.1 9.3 14.0 11.3 11.3 2.5 Min 179.7 178.1145.8 162.0 162.0 136.6 Max 190.6 207.7 200.7 199.2 199.2 145.1

The following clauses described multiple possible embodiments forimplementing the features described in this disclosure. The variousembodiments described herein are not limiting nor is every feature fromany given embodiment required to be present in another embodiment. Anytwo or more of the embodiments may be combined together unless contextclearly indicates otherwise. As used herein in this document “or” meansand/or. For example, “A or B” means A without B, B without A, or A andB. As used herein, “comprising” means including all listed features andpotentially including addition of other features that are not listed.“Consisting essentially of” means including the listed features andthose additional features that do not materially affect the basic andnovel characteristics of the listed features. “Consisting of” means onlythe listed features to the exclusion of any feature not listed.

Clause 1. A device for the intranasal delivery of a compound comprising:

a y-junction including a base, a first branch of the y-junctionradiating from the base, a second branch of the y-junction radiatingfrom the base, a third branch of the y-junction radiating from the base,and an internal dose loading channel of the y-junction;

a metered dose pump in fluid communication with the first branch of they-junction;

a conical spring associated with the second branch of the y-junction;

a dose chamber in fluid communication with the third branch of they-junction;

a nozzle associated with the dose chamber;

a diffuser between the internal dose loading channel and the dosechamber;

an actuator grip surrounding the y-junction; and

a housing, the y-junction residing within the housing.

Clause 2. The device of any of clauses 1-11, further comprising:

a propellant canister in fluid communication with the second branch ofthe y-junction and held by the actuator grip, the conical spring betweenthe propellant canister and the second branch of the y-junction.

Clause 3. The device of any of clauses 1-11, further comprising a vialin fluid communication with the metered dose pump.

Clause 4. The device of clause 3, further comprising a pump fitmentsecuring the metered dose pump to the vial.

Clause 5. The device of any of clauses 1-11, further including acheck-valve associated between the metered dose pump and the y-junction.

Clause 6. The device of any of clauses 1-11, further including a nosecone in engagement with the housing.

Clause 7. The device of clause 6 further comprising a dose cap coveringthe nose cone.

Clause 8. The device of any of clauses 1-11, wherein the third branch ofthe y-junction is at a 45-degree angle from the base of the y-junction.

Clause 9. The device of any of clauses 1-11, wherein the diffuser isannular.

Clause 10. The device of any of clauses 1-11, wherein the diffuser is aporous material.

Clause 11. The device of any of clauses 1-11, wherein the diffuser formsthe bottom of the dose chamber.

Clause 12. A device for the intranasal delivery of a compound, thedevice comprising:

a housing, the housing including a tip, an actuator, and a dose chamber,the tip and the dose chamber in fluid communication within the housing;

a nozzle at a distal portion of the tip, the nozzle providing an outletfor the compound, the nozzle including a plurality of nozzle openings;and

a pump in fluid communication with the dose chamber, the pump to movethe compound into the dose chamber upon actuation of the actuator.

Clause 13. The device of any of clauses 12-15, further comprising apropellant canister associated with the housing, the propellant canisterhaving a propellant valve for actuation by the actuator, the propellantcanister in fluid communication with the dose chamber.

Clause 14. The device of clauses 12-15, further comprising a vial ofcompound associated with the pump to move the compound into the dosechamber from the vial.

Clause 15. The device of clauses 12-15, further including a diffuser.

Clause 16. A device for the intranasal delivery of a compound to theolfactory region of the nasal cavity, the device comprising:

a housing, the housing including a tip, an actuator, and a dose chamber,the tip and the dose chamber in fluid communication with the housing;

a nozzle at a distal portion of the tip, the nozzle providing an outletfor the compound, the nozzle including a plurality of nozzle openings;

a pump in fluid communication with the dose chamber, the pump to movethe compound into the dose chamber upon actuation of the actuator;

a propellant canister associated with the housing, the propellantcanister having a propellant valve for actuation by the actuator, thepropellant canister in fluid communication with the dose chamber; and

a vial of compound associated with the pump to move the compound intothe dose chamber from the vial wherein the actuator upon actuation ofthe device compresses the pump moving the compound into the dose chamberand actuation of the propellant valve disperses the propellant pushingthe compound providing for the compound to exit the device through theplurality of nozzle openings.

Clause 17. A kit including the device any of clauses 1-16, a propellantcanister and a vial.

The present invention is not to be limited in scope by the specificimplementations described herein. Indeed, various modifications of theinvention in addition to those described herein will become apparent tothose skilled in the art from the foregoing description and accompanyingfigures. Such modifications are intended to fall within the scope of theappended claims.

What is claimed is:
 1. A device for the intranasal delivery of acompound comprising: a y-junction including a base, a first branch ofthe y-junction radiating from the base, a second branch of they-junction radiating from the base, a third branch of the y-junctionradiating from the base, and an internal dose loading channel of they-junction; a metered dose pump in fluid communication with the firstbranch of the y-junction; a conical spring associated with the secondbranch of the y-junction; a dose chamber in fluid communication with thethird branch of the y-junction; a nozzle associated with the dosechamber; a diffuser between the internal dose loading channel and thedose chamber; an actuator grip surrounding the y-junction; and ahousing, the y-junction residing within the housing.